




Contents lists available at ScienceDirect

Archives of Biochemistry and Biophysics

journal homepage: www.elsevier.com/locate/yabbi

Review article

Slow-binding inhibition of cholinesterases, pharmacological and toxicological relevance

Patrick Masson ^{a,*}, Sofya V. Lushchekina ^b^a Laboratory of Neuropharmacology, Kazan Federal University, 18, Kremlyovskaya St., Kazan, 420008, Russia^b Laboratory of Computer Modeling of Biomolecular Systems and Nanomaterials, Emanuel Institute of Biochemical Physics of RAS, 4, Kosygina St., Moscow, 119334, Russia

ARTICLE INFO

Article history:

Received 8 December 2015

Received in revised form

20 January 2016

Accepted 5 February 2016

Available online 11 February 2016

Keywords:

Acetylcholinesterase

Butyrylcholinesterase

Slow-binding inhibition

Tight-binding inhibition

Residence time

ABSTRACT

Slow-binding inhibition (SBI) of enzymes is characterized by slow establishment of enzyme-inhibitor equilibrium. Cholinesterases (ChEs) display slow onset of inhibition with certain inhibitors. After a survey of SBI mechanisms, SBI of ChEs is examined. SBI results either from simple slow interaction, induced-fit, or slow conformational selection. In some cases, the slow equilibrium is followed by an irreversible chemical step. This later was observed for the interaction of ChEs with certain irreversible inhibitors. Because slow-binding inhibitors present pharmacological advantages over classical reversible inhibitors (e.g. long target-residence times, resulting in prolonged efficacy with minimal unwanted side effects), slow-binding inhibitors of ChEs are promising new drugs for treatment of Alzheimer disease, myasthenia, and neuroprotection. SBI is also of toxicological importance; it may play a role in mechanisms of resistance and protection against poisoning by irreversible agents.

© 2016 Elsevier Inc. All rights reserved.

Contents

1. Introduction	61
2. Slow-binding inhibition of enzymes	61
2.1. Definition	61
2.2. Detection of slow-binding inhibition	61
2.3. Basic mechanisms	62
2.3.1. Mechanism A	62
2.3.2. Mechanism B	62
2.3.3. Mechanism C	62
2.4. Differentiation between mechanisms	62
2.5. Toxicopharmacological importance of SBI	62
3. Slow-binding inhibition of cholinesterases	63
3.1. SBI of type A	63
3.2. SBI of type B	64
3.3. SBI of type C	65
4. Toxicopharmacological relevance of SBI inhibition of cholinesterases	66
Acknowledgements	67
References	67

Abbreviations: AChE, acetylcholinesterase; BChE, butyrylcholinesterase; ChE, cholinesterase; CSP, cresyl saligenin phosphate; DFP, diisopropylfluorophosphate; DTI, delay time for inhibition; PAS, peripheral anionic site; PD, pharmacodynamics; PK, pharmacokinetics; OP, organophosphorus compound; SBI, slow-binding inhibition; TBI, tight-binding inhibition; TMTFA, *m*-(N,N,N-trimethylammonio)trifluoroacetophenone.

* Corresponding author.

E-mail addresses: pym.masson@free.fr (P. Masson), sofya.lushchekina@gmail.com (S.V. Lushchekina).